Study: Fenofibrate not a useful strategy for decreasing COVID-19 severity

After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant effect on COVID-19 outcomes in a multicenter international randomized clinical trial led by Penn Medicine scientists.

Related Keywords

United States ,America ,American ,Julio Chirinos ,Jordanab Cohen ,Emily Henderson ,Training Program In Cardiovascular Biology ,Lab Diagnostics Automation ,Drug Administration ,University Of Pennsylvania ,American Heart Association Scientific Sessions ,Lab Diagnostics Automation Industry ,Perelman School Of Medicine ,Penn Medicine ,American Heart Association ,Scientific Sessions ,Cardiovascular Medicine ,Cardiovascular Biology ,Perelman School ,United States Food ,Automation Industry Focus ,North America ,South America ,Cholesterol ,Covid 19 ,Fenofibrate ,Clinical Trial ,Drugs ,Efficacy ,Heart ,Hospital ,N Vitro ,Laboratory ,Medicine ,Metabolism ,Placebo ,Research ,Cars ,Virus ,